Perspective Therapeutics updates corporate presentation; highlights 212Pb pipeline with Phase 1/2a data in 2026

Perspective Therapeutics, Inc.

Phase 1/2a data for VMT-α-NET in neuroendocrine tumors shows durable disease control and best-in-class safety profile.
VMT01 (212Pb-MC1R) for melanoma shows preliminary anti-tumor activity and tolerability; combination with checkpoint inhibitors planned.
PSV359 targeting FAP-α for solid tumors demonstrates improved tumor retention; Phase 1/2a trial ongoing.
Phase 1/2 data expected across all three clinical programs in 2026.
Proprietary Pb-based chelator and Lead-212 isotope platform designed to optimize therapeutic index.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.